Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Bioventus (BVS) Shares Issued (2021 - 2026)

Bioventus filings provide 5 years of Shares Issued readings, the most recent being $511000.0 for Q4 2025.

  • On a quarterly basis, Shares Issued fell 53.67% to $511000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 million, a 15.07% decrease, with the full-year FY2025 number at $2.1 million, down 15.07% from a year prior.
  • Shares Issued hit $511000.0 in Q4 2025 for Bioventus, up from $96000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $107.8 million in Q3 2021 to a low of $16000.0 in Q2 2021.
  • Median Shares Issued over the past 5 years was $496500.0 (2022), compared with a mean of $6.6 million.
  • The widest YoY moves for Shares Issued: up 12900.0% in 2022, down 97.98% in 2022.
  • Bioventus' Shares Issued stood at $107.8 million in 2021, then tumbled by 98.99% to $1.1 million in 2022, then plummeted by 85.41% to $158000.0 in 2023, then surged by 598.1% to $1.1 million in 2024, then plummeted by 53.67% to $511000.0 in 2025.
  • The last three reported values for Shares Issued were $511000.0 (Q4 2025), $96000.0 (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.